Serono maintained by Merrill Lynch at buy

Serono was maintained by Merrill Lynch analyst Erica Whittaker at a buy rating with a price target on the stock of CHF 930, based on the expectation that Serono's multiple sclerosis drug Rebif will not lose significant market share if Elan/Biogen Idec's Tysabri returns to the market. Serono shares Tuesday were down CHF 7.00, or 0.83%, at CHF 839.50 on volume of 12,748 shares versus the three-month running average of 33,774 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.